PROVECTUS PV-10 INTERIM PHASE 2 SAFETY AND EFFICACY RESULTS ...
Email this video to your friends
This video has been added to your favorites.
Video Details
Comments
(0)
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported.
To view Multimedia News Release go to http://www.prnewswire.com/mnr/pvct/37429/
Uploaded Mar. 16, 2009
By: comments
0
Views: 114
| Genre: | News Videos |
| Tags: | 2, Trial, Study, Survival, MultiVu, phase, pharmaceuticals, melanoma, clinical, 37429, metastatic, provectus, pv10 |
Share And Linking
Copy and paste this link into an email or instant message
Copy and paste this code to embed this video into your website or blog
Who's Linking
There are currently no sites linking to this video. Copy the code below and be the first site to link or embed the video!
Top Sites Linking To This Video:
Top Rated Comments
There are no rated comments for this video. Rate a comment now.
